CHA₂DS₂-VASc
Stroke Risk
Estimate annual stroke risk in atrial fibrillation and scaffold anticoagulation decision-making.
If anticoagulation is being considered, assess bleeding risk with HAS-BLED (hypertension, abnormal renal/liver, stroke, bleeding, labile INR, elderly, drugs/alcohol). A HAS-BLED score ≥3 warrants further discussion but does not contraindicate anticoagulation.
Score validation and prognostic accuracy
The CHA₂DS₂-VASc score was derived from large European cohorts (16,622 patients with AF across 29 studies) and validates the original CHA₂DS₂ scheme by stratifying intermediate-risk patients. It discriminates stroke risk across all age groups and has superior performance in younger patients (age <65) where it identifies truly low-risk individuals (annual stroke risk <1% without anticoagulation).
ARISTOTLE (apixaban in AF)
Landmark trial (18,201 patients) showing apixaban superior to warfarin for stroke prevention in AF, with lower major bleeding and all-cause mortality. Baseline median CHA₂DS₂-VASc was 3.5; anticoagulation reduced stroke by 21% relative risk.
ROCKET-AF (rivaroxaban in AF)
Large trial (14,264 patients, median CHA₂DS₂-VASc 3.48) demonstrating rivaroxaban non-inferiority to warfarin for stroke/thromboembolism. In subgroup analysis, absolute stroke risk reduction was greater in higher-risk patients (CHA₂DS₂-VASc ≥4).
RE-LY (dabigatran in AF)
Trial of 18,113 patients showing dabigatran 110 mg BID superior to warfarin for major bleeding, and 150 mg BID non-inferior for stroke prevention. Demonstrates that DOAC efficacy is consistent across CHA₂DS₂-VASc risk strata.
ENGAGE AF-TIMI 48 (edoxaban in AF)
Trial of 21,105 patients with AF. Edoxaban 60 mg OD was non-inferior to warfarin for stroke/systemic embolism and superior for major bleeding. Showed consistent benefit across CHA₂DS₂-VASc risk strata in the 30-day DAPT window.
Sex as a biological risk factor in AF
Female sex independently increases stroke risk in AF beyond traditional factors, partly due to higher inflammatory markers and prothrombotic tendencies. The CHA₂DS₂-VASc includes female sex to better identify intermediate-risk women who would otherwise be classified as "low-risk" on CHA₂DS₂ alone.
Very low-risk AF and anticoagulation
In patients with CHA₂DS₂-VASc 0 or 1, absolute stroke risk is <1% per year without anticoagulation. Current international guidelines do not recommend routine anticoagulation in these patients, though individual factors (type of AF, reversibility of risk factors) may change practice.
HealthPathways Canterbury recommends anticoagulation for CHA₂DS₂-VASc ≥2 in men and ≥3 in women, aligning with ESC 2019 guidance. The NZ Cardiac Society position supports this for paroxysmal, persistent, and permanent AF. Consider shared decision-making for borderline risk (score 1-2).
DOACs (apixaban, rivaroxaban, dabigatran, edoxaban) are first-line in primary care AF. They avoid INR monitoring, have fewer drug interactions, and are superior to warfarin for reducing intracranial haemorrhage. Warfarin remains relevant only if: mechanical valve, severe CKD (eGFR <15), patient preference, or cost.
A score of 1 is the "grey zone." Most guidelines suggest anticoagulation for ≥2, but a single point (e.g., age 65-74 alone, or female sex alone) may not warrant it. Document your reasoning and consider whether that single factor is truly active (e.g., recent hypertension diagnosis vs. well-controlled).
If the only reason for a CHA₂DS₂-VASc ≥2 is hypertension that was just diagnosed and is being aggressively treated, consider delaying anticoagulation for 3-6 months while optimising BP, then recalculate. Similarly, if someone has AF triggered by acute coronary syndrome, reassess once acute phase is over.
In moderate-severe CKD (eGFR 15-60), all DOACs are usable but require dose adjustment. Dabigatran is contraindicated in eGFR <30. If eGFR <15, consider warfarin or specialist review. Always check current renal function before prescribing and annually thereafter.
For patients with CHA₂DS₂-VASc ≥2 but bleeding risk concerns, evidence supports using lower-dose DOACs in specific scenarios (age ≥60, weight <60 kg, creatinine >1.5). Document the rationale; this is not "underdosing" but risk-stratified dosing.
Many GPs assume paroxysmal AF is "lower risk" than persistent. This is incorrect-stroke risk is determined by CHA₂DS₂-VASc score, not AF type. However, some patients with AF triggered by treatable causes (alcohol, overweight, sleep apnoea) may have lower recurrence if triggers are addressed.
Aspirin is inferior to anticoagulation for stroke prevention in AF and is no longer recommended as monotherapy in moderate-high-risk patients. It may still be used for secondary prevention if anticoagulation is truly contraindicated, but this is rare with modern DOACs.
Disclaimer: This calculator is a clinical decision-support tool, not a substitute for clinical judgment. CHA₂DS₂-VASc estimates group-level annual stroke risk; individual risk may vary. Always assess HAS-BLED (bleeding risk), renal function, drug interactions, and patient preferences before prescribing anticoagulation. Consult current HealthPathways, NZ Cardiac Society, or ESC guidelines for the most up-to-date recommendations.